Table 4.

Cumulative Incidence of Invasive Fungal Disease and Other Outcomes by Main Study Group

Study Outcome	Caspofungin (n = 144)		Combined Triazole or Specific Triazole for Subgroup Analysis (n = 146)		P-value
	Events	Probability (95% CI)	Events	Probability (95% CI)
Primary outcome
Proven or probable IFD at day 42	2	1.4 (0.3–5.4)	2	1.4 (0.4–5.5)	.99
Exploratory outcomes
Proven or probable IFD at day 100	4	2.8 (1.1–7.3)	5	3.6 (1.5–8.4)	.73
Proven or probable IFD at day 42
Caspofungin vs. fluconazole	2	1.4 (0.3–5.4)	1	1.0 (0.1–6.9)	.78
Caspofungin vs. voriconazole	2	1.4 (0.3–5.4)	1	2.3 (0.3–15.1)	.69
Proven or probable IFD at day 100 stratified by triazole
Caspofungin vs. fluconazole	4	2.8 (1.1–7.3)	4	4.2 (1.6–10.7)	.59
Caspofungin vs. voriconazole	4	2.8 (1.1–7.3)	1	2.3 (0.3–15.1)	.85
Fungal-free survival
At day 42	3	97.9 (93.7–99.3)	3	97.9 (93.7–99.3)	.99
At day 100	8	94.3 (88.9–97.1)	13	90.8 (84.8–94.6)	.26
Proportion with acute GVHD
Grade I-IV	58	40.3 (32.3–48.3)	64	43.8 (35.8–51.9)	.54
Grade II-IV	38	26.4 (19.2–33.6)	43	29.5 (22.1–36.9)	.56
Grade III-IV	17	11.8 (6.5–17.1)	25	17.1 (11.0–23.2)	.2
Post hoc outcomes
Proven, probable, or possible IFD
At day 42	4	2.8 (1.1–7.3)	6	4.2 (1.9–9.1)	.52
At day 100	7	4.9 (2.4–10.1)	9	6.3 (3.3–11.8)	.59
Overall survival at day 100	4	97.2 (92.7–98.9)	8	94.4 (89.2–97.2)	.25
Treatment-related mortality at day 100	2	1.4 (0.3–5.4)	4	2.8 (1.1–7.3)	.41

Abbreviations: CI, Confidence Interval; IFD, Invasive Fungal Disease; GVHD, Graft-vs-Host Disease.